NASDAQ:KDNY

Chinook Therapeutics Stock Forecast, Price & News

$17.36

+0.13 (+0.75 %)

(As of 03/2/2021 12:00 AM ET)

Add

Compare

Today's Range

$16.62

Now: $17.36▼

$17.64

50-Day Range

$14.17

MA: $15.48▼

$17.23

52-Week Range

$9.35

Now: $17.36▼

$21.68

Volume104,077 shs

Average Volume101,444 shs

Market Capitalization$731.86 million

P/E RatioN/A

Dividend YieldN/A

Beta0.26

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.

Headlines

Will Chinook Therapeutics (KDNY) Report Negative Q4 Earnings? What You Should Know
March 1, 2021 | finance.yahoo.com

Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
March 1, 2021 | finance.yahoo.com

Evotec, Chinook Collaborate To Discover & Develop Medicines For Chronic Kidney Diseases
March 1, 2021 | nasdaq.com

Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit
February 23, 2021 | finance.yahoo.com

Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 17, 2021 | finance.yahoo.com

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria
February 2, 2021 | finance.yahoo.com

Who Has Been Buying Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares?
January 7, 2021 | finance.yahoo.com

Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities
December 8, 2020 | finance.yahoo.com

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2020 | finance.yahoo.com

Chinook Therapeutics to Present at Upcoming Investor Conferences
November 18, 2020 | finance.yahoo.com

Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer
November 10, 2020 | finance.yahoo.com

Aduro Biotech (KDNY) Reports Q3 Loss, Tops Revenue Estimates
November 5, 2020 | nasdaq.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KDNY

Previous Symbol

CUSIPN/A

CIKN/A

Webchinooktx.com

Phone510-848-4400

Employees43

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio11.27

Quick Ratio11.27

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$17.26 million

Price / Sales42.40

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.07 per share

Price / Book4.27

Profitability

EPS (Most Recent Fiscal Year)($5.15)

Net Income$-82,370,000.00

Net Margins-215.80%

Return on Equity-112.72%

Return on Assets-21.36%

Miscellaneous

Outstanding Shares42,158,000

Market Cap$731.86 million

Next Earnings Date3/8/2021 (Estimated)

OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.55 out of 5 stars

Medical Sector

384th out of 1,969 stocks

Pharmaceutical Preparations Industry

198th out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
Chinook Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.33, Chinook Therapeutics has a forecasted upside of 74.7% from its current price of $17.36.
Amount of Analyst Coverage
Chinook Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Chinook Therapeutics has received 10 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Chinook Therapeutics has received 8 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Chinook Therapeutics has received 55.56% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Chinook Therapeutics and other stocks. Vote “Outperform” if you believe KDNY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KDNY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Chinook Therapeutics does not currently pay a dividend.
Dividend Growth
Chinook Therapeutics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chinook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,480.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Chinook Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Chinook Therapeutics are expected to grow in the coming year, from ($1.97) to ($1.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chinook Therapeutics is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chinook Therapeutics is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Chinook Therapeutics has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$17.36

+0.13 (+0.75 %)

(As of 03/2/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KDNY News and Ratings via Email

Sign-up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter.

Chinook Therapeutics (NASDAQ:KDNY) Frequently Asked Questions

Is Chinook Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chinook Therapeutics stock.
View analyst ratings for Chinook Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Chinook Therapeutics?

Wall Street analysts have given Chinook Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chinook Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chinook Therapeutics' next earnings date?

Chinook Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Chinook Therapeutics.

What price target have analysts set for KDNY?

7 brokerages have issued 12 month price objectives for Chinook Therapeutics' stock. Their forecasts range from $25.00 to $38.00. On average, they expect Chinook Therapeutics' share price to reach $30.33 in the next twelve months. This suggests a possible upside of 74.7% from the stock's current price.
View analysts' price targets for Chinook Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Chinook Therapeutics' key executives?

Chinook Therapeutics' management team includes the following people:

Mr. Eric L. Dobmeier, Pres, CEO & Director (Age 52)
Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 61)
Ms. Noopur Batsha Liffick, VP of Investor Relations & Corp. Communications
Mr. Kirk D. Schumacher J.D., Sr. VP & Gen. Counsel
Ms. Jodi Jamieson, VP of HR
Mr. Tom Frohlich, Chief Bus. Officer
Mr. Alan Glicklich M.D., Chief Medical Officer
Mr. Andrew James King D.V.M., Ph.D., Head of Renal Discovery & Translational Medicine
Ms. Renata Oballa Ph.D., VP of Chemistry & Vancouver Site Head

Who are some of Chinook Therapeutics' key competitors?

Some companies that are related to Chinook Therapeutics include Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), Viela Bio (VIE), CytoDyn (CYDY), Intra-Cellular Therapies (ITCI), Taro Pharmaceutical Industries (TARO), IGM Biosciences (IGMS), Global Blood Therapeutics (GBT), Prelude Therapeutics (PRLD), Xencor (XNCR), Axsome Therapeutics (AXSM), Arcus Biosciences (RCUS), Deciphera Pharmaceuticals (DCPH), Ligand Pharmaceuticals (LGND) and Amarin (AMRN).
View all of KDNY's competitors.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent Inc. (RX.V) (RX) and Continental Resources (CLR).

What is Chinook Therapeutics' stock symbol?

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

Who are Chinook Therapeutics' major shareholders?

Chinook Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Samsara BioCapital LLC (7.52%), BlackRock Inc. (3.34%), Orbimed Advisors LLC (2.97%), Baillie Gifford & Co. (2.00%), Renaissance Technologies LLC (1.98%) and Baker BROS. Advisors LP (1.78%).
View institutional ownership trends for Chinook Therapeutics.

Which major investors are selling Chinook Therapeutics stock?

KDNY stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., and Panagora Asset Management Inc..
View insider buying and selling activity for Chinook Therapeutics or view top insider-selling stocks.

Which major investors are buying Chinook Therapeutics stock?

KDNY stock was bought by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, BlackRock Inc., Orbimed Advisors LLC, Renaissance Technologies LLC, Baker BROS. Advisors LP, Monashee Investment Management LLC, Northern Trust Corp, and JPMorgan Chase & Co..
View insider buying and selling activity for Chinook Therapeutics or or view top insider-buying stocks.

How do I buy shares of Chinook Therapeutics?

Shares of KDNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chinook Therapeutics' stock price today?

One share of KDNY stock can currently be purchased for approximately $17.36.

How much money does Chinook Therapeutics make?

Chinook Therapeutics has a market capitalization of $731.86 million and generates $17.26 million in revenue each year. The company earns $-82,370,000.00 in net income (profit) each year or ($5.15) on an earnings per share basis.

How many employees does Chinook Therapeutics have?

Chinook Therapeutics employs 43 workers across the globe.

What is Chinook Therapeutics' official website?

The official website for Chinook Therapeutics is chinooktx.com.

Where are Chinook Therapeutics' headquarters?

Chinook Therapeutics is headquartered at 740 HEINZ AVENUE, BERKELEY CA, 94710.

How can I contact Chinook Therapeutics?

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The company can be reached via phone at 510-848-4400 or via email at [email protected]

This page was last updated on 3/3/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here